Corneal crosslinking technology (CXL) update
ESCRS members schooled their colleagues on CXL technology at the 2016 AAO Annual Meeting


Howard Larkin
Published: Tuesday, November 1, 2016

Rudy Nuijts
Published: Tuesday, November 1, 2016
[caption id="attachment_5992" align="alignnone" width="750"]
David Touboul MD presents on CXL with corneal rings as Rudy Nuijts MD, PhD and Thomas Kohnen MD, PhD look on.[/caption]
With corneal crosslinking (CXL) finally approved this year by the US Food and Drug Administration, ESCRS members schooled their American colleagues on the latest in CXL technology at Refractive Surgery Subspecialty Day, sponsored by the International Society of Refractive Surgery, at the 2016 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago.
In his review of indications and long-term outcomes for CXL in keratoconus, Rudy MMA Nuijts MD, PhD, of the Academic Hospital Maastricht, The Netherlands, noted that standard Dresden Protocol CXL provides stable long-term results for visual acuity and keratometry in 90% of patients.
In children, epithelium-off CXL provides persistent treatment effect up to four years in 80-90% of patients.
Preliminary data suggests CXL will lead to a decrease of at least 25% in corneal transplants for keratoconus. Topography-guided photorefractive keratectomy (PRK) combined with CXL has proven an effective treatment for post-LASIK ectasia and visual rehabilitation over 12 years, said A John Kanellopoulos MD of Athens, Greece, and New York University, USA.
Other presenters were Thomas Kohnen MD, PhD, of Goethe University Frankfurt, Germany, on accelerated CXL; David Touboul MD, of the University of Bordeaux, France, on CXL with corneal rings; and Simonetta Morselli MD, of the University of Verona, Italy, on CXL for treating corneal infections.

Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.